Health Economics Summer School 2007

14:00 Welcome and introduction to the program

Michael Schlander

14:30 Economic welfare theory and health economics

Friedrich Breyer

15:30 The logic of cost-effectiveness ("extra-welfarism")

Martin J. Buxton

16:30 Coffee Break

17:00 The ethics of priority setting in health care

Sören Holm

18:00 Re-interpreting health economics

Jeff Richardson

19:00 Supper Break

20:00 Roundtable discussion – The "dismal science" revisited:
Normative foundations of health economic analysis

Friedrich Breyer
Martin J. Buxton
Sören Holm
Jeff Richardson
Michael Schlander

9:00 National Institute for Health and Clinical Excellence (NICE)

Martin J. Buxton

• Mission and roles of NICE
• The NICE reference case
• NICE processes and procedures
• How does NICE come to its decisions?
• How do NICE and the Scottish Medicines Consortium (SMC) relate?

10:30 Coffee Break

11:00 NICE and the National Health Service (NHS)

Martin J. Buxton

• Implementation issues
• Is the current ICER threshold right?
• Value-based pricing - possible future developments

12:30 Lunch Break

14:00 The Australian experience

Rosalie Viney
Jeff Richardson

• Pharmaceutical Benefits Scheme (PBS) in Australia
• Pharmaceutical Benefits Advisory Committee (PBAC)
• Quality of submissions to PBAC - common flaws
• Can the system be "played" by companies?

15:30 Coffee Break

16:00 The Canadian experience

Andreas Laupacis

• The Canadian Common Drug Review (CDR)
• CDR appraisal processes
• Canadian Expert Drug Advisory Committee (CEDAC) Canadian Agency for Drugs and Technologies in Health (CADTH)
• Provincial formulary listing in Canada

17:30 Break

19:00 Social program & dinner

9:00 Economic analysis and medical decision-making: help or hindrance? A North American perspective

Andreas Laupacis

• Prescription creep and implementation issues
• Usefulness of economic evaluations
• Canadian drug policy and pharmacoeconomics
• Expensive drugs for rare diseases in Canada
• Recent trends in the United States

10:30 Coffee Break

11:00 Health Technology Assessments in Europe

Panos Kanavos

• Assessment procedures and methods in Europe
• HTAs and decision-making in Europe
• Evidence and innovation in health care
• Interface between HTAs and innovation

12:30 Lunch Break

14:00 Pharmaceutical price regulation in the UK

Panos Kanavos

• Reforming the UK Pharmaceutical Price Regulation Scheme (PPRS)
• Moving towards value-based pricing in the UK?
• Implications for stakeholders

15:00 The Swedish experience

Ulf Persson

• The Pharmaceutical Benefits Board (LNF)
• Applying the cost-effectiveness principle
• Experience, issues and debate in Sweden

16:30 Coffee Break

17:00 The German approach to economic evaluation

Peter Kolominsky-Rabas

• Legal and regulatory environment
• Mission and roles of IQWiG
• HTAs in Germany
• Objectives of health economic evaluations by IQWiG

18:30 Supper Break

20:00 Roundtable discussion:
Value-based pricing: a NICE approach?

Andreas Laupacis
Panos Kanavos
Peter Kolominsky-Rabas
Ulf Persson
Michael Schlander

9:00 Stakeholder expectations I

Koen Torfs

• A research-based pharmaceutical corporation’s view

10:00 The perspective of patients

Christine Lavery

11:00 Coffee Break

11:30 Stakeholder expectations II

Wolfgang Kaesbach

• The perspective of payers in the regulatory context

12:30 Discussion

13:00 Which way forward?

Michael Schlander

• What have we learnt?
• Concluding remarks

13:30 Lunch (optional)